Jefferies maintains a 'buy' rating on Smith & Nephew with a 1,500p price target despite investor doubts about achieving 5.0%-5.5% organic sales growth in the second half of 2026. The company lowered its full-year sales growth guidance to 4% from 6%, with challenges including regulatory changes, tariff impacts, and the unexpected CFO departure. Activist shareholder Cevian holds over 14%, and strategic options like an orthopaedics sale or spin-off are being considered. A key upcoming event is the early-2027 trial readout for MediWound's EscharEx, which could impact Smith & Nephew's Santyl product.
VinFast Auto Ltd. is set to release its Q3 2026 earnings with analysts expecting a loss per share of $0.33 and revenues around $1.15 billion. The Vietnamese electric vehicle maker is expanding internationally, promoting its VF 9 SUV in Canada and ben...
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
Tiger Gold Corp. has filed a final short form prospectus and received regulatory approval to distribute over 25.6 million units and approximately 405,000 compensation options following the deemed exercise of special warrants issued in June 2026. Each...
Hargreaves Lansdown, the UK's largest retail investment platform, now offers nine Bitcoin and Ether exchange-traded notes (ETNs) from major asset managers. This marks a shift from its previous cautious stance on crypto, enabled by updated UK regulati...
Digital asset exchange-traded products (ETPs) saw their strongest rebound of 2026 in August, with assets under management (AUM) rising 27.2% to $138.2 billion, surpassing the broader digital asset market's 21.2% growth. Bitcoin-backed ETPs increased ...
